However, in a TME with certain tumor-infiltrating leukocytes (such as B16 melanoma), activating rather than inhibiting p53 locally could enhance CD8 CTLs and antitumor immunity (Guo et al., 2017). This evidence concerns the gene TP53 and melanoma.